Update from Biogen
In a community statement shared today, April 8, 2026, Biogen provided an update on its omaveloxolone clinical development program, including:
- BRAVE Phase 3 pediatric study reaching 50% enrollment
- The official conclusion of the MOXIe Open‑Label Extension study, with sincere thanks to the community
- An ongoing study to assess the bioequivalence of a tablet form of omaveloxolone that is suspended in liquid relative to the oral capsule
Read the full statement at the link below.
